| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Respiration | 43 | 2025 | 281 | 10.500 |
Why?
|
| Respiratory Center | 28 | 2025 | 57 | 6.860 |
Why?
|
| Neurons | 47 | 2025 | 1654 | 6.150 |
Why?
|
| Nerve Net | 35 | 2025 | 407 | 5.000 |
Why?
|
| Respiratory Insufficiency | 9 | 2025 | 205 | 4.720 |
Why?
|
| Medulla Oblongata | 17 | 2025 | 95 | 3.940 |
Why?
|
| Respiratory Mechanics | 19 | 2014 | 114 | 3.520 |
Why?
|
| Periodicity | 17 | 2019 | 119 | 3.360 |
Why?
|
| Brain Stem | 19 | 2025 | 170 | 3.120 |
Why?
|
| Hypoxia | 18 | 2024 | 681 | 2.910 |
Why?
|
| Sudden Infant Death | 8 | 2024 | 34 | 2.670 |
Why?
|
| Rett Syndrome | 8 | 2022 | 20 | 2.560 |
Why?
|
| Analgesics, Opioid | 7 | 2025 | 513 | 2.520 |
Why?
|
| Models, Neurological | 10 | 2025 | 435 | 2.470 |
Why?
|
| Action Potentials | 23 | 2025 | 618 | 2.330 |
Why?
|
| Biological Clocks | 14 | 2011 | 81 | 2.240 |
Why?
|
| Mice | 76 | 2025 | 12537 | 2.080 |
Why?
|
| Synaptic Transmission | 15 | 2022 | 233 | 2.060 |
Why?
|
| Animals | 102 | 2025 | 28889 | 2.020 |
Why?
|
| Neuronal Plasticity | 9 | 2023 | 205 | 1.900 |
Why?
|
| Deglutition | 3 | 2024 | 85 | 1.730 |
Why?
|
| Arousal | 7 | 2022 | 173 | 1.630 |
Why?
|
| Inhalation | 5 | 2021 | 34 | 1.620 |
Why?
|
| Autonomic Nervous System Diseases | 4 | 2023 | 24 | 1.550 |
Why?
|
| Respiration Disorders | 4 | 2022 | 42 | 1.330 |
Why?
|
| Optogenetics | 4 | 2025 | 46 | 1.290 |
Why?
|
| Interneurons | 6 | 2025 | 106 | 1.230 |
Why?
|
| Sleep Apnea, Obstructive | 4 | 2024 | 220 | 1.220 |
Why?
|
| Neuroglia | 4 | 2025 | 105 | 1.180 |
Why?
|
| Neural Inhibition | 8 | 2018 | 108 | 1.160 |
Why?
|
| Dependovirus | 3 | 2025 | 37 | 1.130 |
Why?
|
| Mice, Inbred C57BL | 17 | 2025 | 3491 | 1.090 |
Why?
|
| Respiratory Physiological Phenomena | 4 | 2014 | 49 | 1.080 |
Why?
|
| Leigh Disease | 3 | 2024 | 4 | 1.080 |
Why?
|
| Fentanyl | 2 | 2025 | 87 | 1.070 |
Why?
|
| Respiratory System | 8 | 2023 | 120 | 1.060 |
Why?
|
| Motor Neurons | 6 | 2025 | 178 | 1.000 |
Why?
|
| Central Nervous System | 4 | 2018 | 153 | 1.000 |
Why?
|
| Larynx | 2 | 2023 | 35 | 0.970 |
Why?
|
| Calcium | 6 | 2023 | 1205 | 0.960 |
Why?
|
| Brain | 9 | 2025 | 2479 | 0.950 |
Why?
|
| Sodium | 3 | 2025 | 340 | 0.910 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 2 | 2025 | 89 | 0.900 |
Why?
|
| Animals, Newborn | 19 | 2021 | 536 | 0.890 |
Why?
|
| In Vitro Techniques | 23 | 2014 | 1008 | 0.890 |
Why?
|
| Rabies virus | 1 | 2024 | 6 | 0.890 |
Why?
|
| Mice, Transgenic | 13 | 2025 | 1645 | 0.880 |
Why?
|
| Neocortex | 6 | 2012 | 106 | 0.880 |
Why?
|
| Efferent Pathways | 1 | 2024 | 22 | 0.880 |
Why?
|
| Oxygen | 6 | 2022 | 781 | 0.830 |
Why?
|
| Long-Term Potentiation | 2 | 2023 | 51 | 0.830 |
Why?
|
| Central Pattern Generators | 2 | 2021 | 4 | 0.820 |
Why?
|
| Autonomic Nervous System | 3 | 2023 | 68 | 0.810 |
Why?
|
| Whole Genome Sequencing | 1 | 2024 | 109 | 0.810 |
Why?
|
| Oligodendroglia | 1 | 2024 | 122 | 0.800 |
Why?
|
| Morphine | 1 | 2023 | 130 | 0.760 |
Why?
|
| Mammals | 3 | 2018 | 261 | 0.760 |
Why?
|
| Neurodegenerative Diseases | 1 | 2023 | 58 | 0.750 |
Why?
|
| Neurotransmitter Agents | 3 | 2019 | 111 | 0.730 |
Why?
|
| Nervous System Diseases | 1 | 2023 | 172 | 0.730 |
Why?
|
| Sneezing | 1 | 2022 | 36 | 0.720 |
Why?
|
| Ion Channels | 5 | 2025 | 260 | 0.720 |
Why?
|
| Receptors, Opioid, mu | 1 | 2021 | 49 | 0.690 |
Why?
|
| Patch-Clamp Techniques | 14 | 2025 | 402 | 0.690 |
Why?
|
| Isoflurane | 4 | 2024 | 69 | 0.690 |
Why?
|
| Humans | 58 | 2025 | 95799 | 0.690 |
Why?
|
| Neural Pathways | 5 | 2025 | 333 | 0.680 |
Why?
|
| Anesthetics, Inhalation | 4 | 2024 | 102 | 0.680 |
Why?
|
| Hypoxia, Brain | 4 | 2018 | 43 | 0.660 |
Why?
|
| Emotions | 2 | 2022 | 377 | 0.650 |
Why?
|
| Neurophysiology | 1 | 2020 | 14 | 0.640 |
Why?
|
| Oxygen Consumption | 3 | 2010 | 253 | 0.640 |
Why?
|
| Sodium Channels | 7 | 2012 | 131 | 0.630 |
Why?
|
| Editorial Policies | 1 | 2020 | 33 | 0.630 |
Why?
|
| Substantia Nigra | 3 | 2025 | 30 | 0.620 |
Why?
|
| Substance P | 5 | 2019 | 62 | 0.590 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 398 | 0.590 |
Why?
|
| Transcriptome | 2 | 2024 | 770 | 0.580 |
Why?
|
| Male | 39 | 2025 | 45685 | 0.560 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 171 | 0.550 |
Why?
|
| Calcium Channels | 4 | 2007 | 183 | 0.540 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 2474 | 0.530 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 232 | 0.520 |
Why?
|
| Synapses | 5 | 2016 | 291 | 0.520 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2018 | 188 | 0.510 |
Why?
|
| Child | 14 | 2023 | 7618 | 0.500 |
Why?
|
| Neurogenesis | 5 | 2019 | 90 | 0.490 |
Why?
|
| Vesicular Glutamate Transport Protein 2 | 3 | 2024 | 6 | 0.490 |
Why?
|
| Electron Transport Complex I | 6 | 2024 | 34 | 0.490 |
Why?
|
| Dentate Gyrus | 4 | 2021 | 33 | 0.490 |
Why?
|
| Carbon Dioxide | 1 | 2017 | 212 | 0.490 |
Why?
|
| Respiratory Burst | 3 | 2006 | 19 | 0.480 |
Why?
|
| Disease Models, Animal | 9 | 2025 | 2534 | 0.470 |
Why?
|
| Hippocampus | 2 | 2011 | 459 | 0.470 |
Why?
|
| Environmental Exposure | 1 | 2018 | 356 | 0.460 |
Why?
|
| Pulmonary Ventilation | 2 | 2013 | 33 | 0.460 |
Why?
|
| Female | 37 | 2024 | 49869 | 0.460 |
Why?
|
| Infant | 9 | 2024 | 3360 | 0.440 |
Why?
|
| Dinoprostone | 2 | 2014 | 75 | 0.440 |
Why?
|
| Lip | 1 | 2014 | 17 | 0.430 |
Why?
|
| Organ Culture Techniques | 7 | 2021 | 128 | 0.430 |
Why?
|
| Seizures | 3 | 2022 | 331 | 0.410 |
Why?
|
| Calcium Channels, N-Type | 1 | 2013 | 18 | 0.390 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2013 | 36 | 0.390 |
Why?
|
| Polysomnography | 3 | 2013 | 155 | 0.390 |
Why?
|
| Norepinephrine | 3 | 2014 | 173 | 0.390 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 182 | 0.380 |
Why?
|
| Hyperthermia, Induced | 2 | 2004 | 75 | 0.370 |
Why?
|
| Sex Characteristics | 2 | 2020 | 340 | 0.370 |
Why?
|
| Parkinson Disease | 2 | 2025 | 178 | 0.360 |
Why?
|
| Homeodomain Proteins | 4 | 2025 | 563 | 0.350 |
Why?
|
| Invertebrates | 1 | 2011 | 36 | 0.350 |
Why?
|
| Pyramidal Cells | 4 | 2016 | 89 | 0.350 |
Why?
|
| Oxidants | 1 | 2011 | 86 | 0.340 |
Why?
|
| Infant, Premature | 1 | 2013 | 308 | 0.340 |
Why?
|
| Lung Diseases | 1 | 2013 | 288 | 0.340 |
Why?
|
| Cholinergic Neurons | 2 | 2024 | 11 | 0.340 |
Why?
|
| Tetrodotoxin | 7 | 2012 | 51 | 0.340 |
Why?
|
| Adaptation, Physiological | 3 | 2008 | 340 | 0.330 |
Why?
|
| Hydrogen Peroxide | 1 | 2011 | 165 | 0.330 |
Why?
|
| Vertebrates | 1 | 2011 | 113 | 0.320 |
Why?
|
| Flufenamic Acid | 6 | 2014 | 13 | 0.310 |
Why?
|
| Sleep | 3 | 2022 | 459 | 0.310 |
Why?
|
| Excitatory Postsynaptic Potentials | 5 | 2018 | 90 | 0.300 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 4 | 2020 | 17 | 0.300 |
Why?
|
| Seals, Earless | 1 | 2008 | 1 | 0.300 |
Why?
|
| Prosencephalon | 2 | 2025 | 68 | 0.290 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2008 | 27 | 0.290 |
Why?
|
| Behavior, Animal | 1 | 2011 | 394 | 0.280 |
Why?
|
| Dopaminergic Neurons | 2 | 2025 | 30 | 0.270 |
Why?
|
| Riluzole | 5 | 2014 | 17 | 0.270 |
Why?
|
| Homeostasis | 3 | 2018 | 467 | 0.260 |
Why?
|
| Wakefulness | 2 | 2012 | 138 | 0.260 |
Why?
|
| Epilepsy | 3 | 2022 | 452 | 0.260 |
Why?
|
| Biophysics | 3 | 2019 | 157 | 0.250 |
Why?
|
| Infant, Newborn | 5 | 2024 | 2610 | 0.240 |
Why?
|
| Heart Rate | 3 | 2012 | 518 | 0.240 |
Why?
|
| Respiratory Rate | 3 | 2023 | 25 | 0.240 |
Why?
|
| Transcription Factors | 3 | 2025 | 1730 | 0.240 |
Why?
|
| Electric Stimulation | 5 | 2011 | 397 | 0.240 |
Why?
|
| Psychophysiology | 2 | 2022 | 9 | 0.240 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 4 | 2012 | 90 | 0.230 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2006 | 50 | 0.230 |
Why?
|
| Toxins, Biological | 1 | 2025 | 8 | 0.230 |
Why?
|
| Child, Preschool | 7 | 2020 | 3970 | 0.230 |
Why?
|
| NAV1.1 Voltage-Gated Sodium Channel | 1 | 2025 | 8 | 0.230 |
Why?
|
| Acetylcholine | 2 | 2019 | 180 | 0.230 |
Why?
|
| Antiparkinson Agents | 1 | 2025 | 16 | 0.220 |
Why?
|
| Neuroanatomical Tract-Tracing Techniques | 1 | 2024 | 2 | 0.220 |
Why?
|
| Levodopa | 1 | 2025 | 36 | 0.220 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2025 | 21 | 0.220 |
Why?
|
| Birds | 1 | 2007 | 173 | 0.220 |
Why?
|
| Afferent Pathways | 1 | 2024 | 78 | 0.210 |
Why?
|
| Intellectual Disability | 2 | 2022 | 203 | 0.210 |
Why?
|
| Computer Simulation | 2 | 2025 | 1158 | 0.210 |
Why?
|
| Genetic Therapy | 2 | 2025 | 382 | 0.210 |
Why?
|
| Murinae | 1 | 2023 | 5 | 0.210 |
Why?
|
| Evoked Potentials | 2 | 2013 | 202 | 0.200 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2025 | 122 | 0.200 |
Why?
|
| Stillbirth | 1 | 2023 | 14 | 0.200 |
Why?
|
| Cadmium | 5 | 2014 | 30 | 0.200 |
Why?
|
| Mice, Knockout | 7 | 2024 | 2161 | 0.200 |
Why?
|
| Albuterol | 1 | 2023 | 35 | 0.200 |
Why?
|
| Oxazines | 1 | 2023 | 15 | 0.200 |
Why?
|
| Exhalation | 1 | 2023 | 13 | 0.200 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 1 | 2023 | 17 | 0.200 |
Why?
|
| Epinephrine | 1 | 2023 | 92 | 0.200 |
Why?
|
| Bronchodilator Agents | 1 | 2023 | 70 | 0.200 |
Why?
|
| Excitatory Amino Acid Antagonists | 5 | 2011 | 82 | 0.200 |
Why?
|
| Fetal Growth Retardation | 1 | 2023 | 72 | 0.200 |
Why?
|
| Gonorrhea | 1 | 2023 | 24 | 0.190 |
Why?
|
| Circadian Rhythm | 2 | 2020 | 299 | 0.190 |
Why?
|
| Consciousness Disorders | 1 | 2023 | 13 | 0.190 |
Why?
|
| Receptors, Serotonin | 1 | 2002 | 34 | 0.190 |
Why?
|
| Caenorhabditis elegans | 1 | 2025 | 246 | 0.190 |
Why?
|
| Astrocytes | 1 | 2023 | 151 | 0.190 |
Why?
|
| Coma | 1 | 2023 | 52 | 0.190 |
Why?
|
| Tachykinins | 1 | 2002 | 13 | 0.190 |
Why?
|
| Electrophysiology | 5 | 2008 | 406 | 0.190 |
Why?
|
| Peripheral Nervous System | 1 | 2002 | 21 | 0.190 |
Why?
|
| Gene Frequency | 1 | 2024 | 703 | 0.180 |
Why?
|
| Fever | 1 | 2003 | 131 | 0.180 |
Why?
|
| Hypoglossal Nerve | 2 | 2013 | 27 | 0.180 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 2021 | 21 | 0.180 |
Why?
|
| Protein Precursors | 1 | 2002 | 138 | 0.180 |
Why?
|
| Sodium Channel Blockers | 5 | 2014 | 29 | 0.180 |
Why?
|
| Drug Interactions | 4 | 2011 | 245 | 0.170 |
Why?
|
| Heat-Shock Response | 1 | 2002 | 54 | 0.170 |
Why?
|
| Parkinsonian Disorders | 1 | 2021 | 22 | 0.170 |
Why?
|
| Hepatitis C | 1 | 2023 | 184 | 0.170 |
Why?
|
| Heat-Shock Proteins | 1 | 2002 | 183 | 0.170 |
Why?
|
| Deglutition Disorders | 1 | 2022 | 126 | 0.170 |
Why?
|
| Cytoskeletal Proteins | 1 | 2021 | 227 | 0.160 |
Why?
|
| Dysautonomia, Familial | 2 | 2011 | 2 | 0.160 |
Why?
|
| Skin | 1 | 2023 | 604 | 0.160 |
Why?
|
| Time Factors | 5 | 2016 | 5561 | 0.160 |
Why?
|
| Strychnine | 2 | 2018 | 7 | 0.160 |
Why?
|
| Risk Factors | 5 | 2023 | 5961 | 0.160 |
Why?
|
| Potassium Channel Blockers | 2 | 2013 | 67 | 0.150 |
Why?
|
| Signal Transduction | 4 | 2023 | 3581 | 0.150 |
Why?
|
| Case-Control Studies | 4 | 2023 | 1957 | 0.140 |
Why?
|
| Serotonin Antagonists | 3 | 2010 | 35 | 0.140 |
Why?
|
| Lung | 1 | 2005 | 1380 | 0.140 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 2 | 2010 | 7 | 0.140 |
Why?
|
| Cluster Analysis | 3 | 2017 | 393 | 0.140 |
Why?
|
| Vagotomy | 1 | 2018 | 12 | 0.140 |
Why?
|
| Smoking | 2 | 2019 | 649 | 0.140 |
Why?
|
| Cerebral Cortex | 3 | 2021 | 615 | 0.140 |
Why?
|
| Pyridazines | 1 | 2018 | 22 | 0.140 |
Why?
|
| Diving | 2 | 2008 | 5 | 0.140 |
Why?
|
| Plethysmography | 2 | 2008 | 18 | 0.140 |
Why?
|
| Nonlinear Dynamics | 1 | 2018 | 74 | 0.140 |
Why?
|
| HEK293 Cells | 3 | 2025 | 706 | 0.130 |
Why?
|
| Feedback, Physiological | 1 | 2018 | 69 | 0.130 |
Why?
|
| Oxidative Stress | 1 | 2020 | 473 | 0.130 |
Why?
|
| Genetic Variation | 1 | 2024 | 1422 | 0.130 |
Why?
|
| Peptides | 1 | 2021 | 671 | 0.130 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 3 | 2011 | 14 | 0.130 |
Why?
|
| RNA | 1 | 2021 | 604 | 0.130 |
Why?
|
| Pregnancy Outcome | 1 | 2019 | 273 | 0.130 |
Why?
|
| Cell Hypoxia | 2 | 2008 | 187 | 0.130 |
Why?
|
| Neural Stem Cells | 2 | 2018 | 69 | 0.130 |
Why?
|
| Cognition | 1 | 2022 | 635 | 0.130 |
Why?
|
| Mice, Inbred Strains | 3 | 2012 | 297 | 0.130 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2016 | 44 | 0.120 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2016 | 87 | 0.120 |
Why?
|
| Mutation | 3 | 2013 | 4374 | 0.120 |
Why?
|
| Glutamine | 1 | 2016 | 99 | 0.120 |
Why?
|
| GABA Antagonists | 3 | 2011 | 26 | 0.120 |
Why?
|
| Smoking Cessation | 1 | 2019 | 272 | 0.120 |
Why?
|
| Cocaine | 1 | 2016 | 81 | 0.120 |
Why?
|
| Nucleus Accumbens | 1 | 2016 | 113 | 0.120 |
Why?
|
| Progesterone | 1 | 2015 | 112 | 0.110 |
Why?
|
| Retrospective Studies | 4 | 2023 | 10273 | 0.110 |
Why?
|
| Encephalitis | 1 | 2015 | 101 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 173 | 0.110 |
Why?
|
| Potassium | 3 | 2004 | 271 | 0.110 |
Why?
|
| Cell Nucleus | 1 | 2017 | 618 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2016 | 1965 | 0.110 |
Why?
|
| Glioblastoma | 1 | 2017 | 285 | 0.110 |
Why?
|
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 2 | 2011 | 14 | 0.110 |
Why?
|
| United States | 6 | 2023 | 7764 | 0.110 |
Why?
|
| N-Methylaspartate | 2 | 2010 | 50 | 0.100 |
Why?
|
| Excitatory Amino Acid Agonists | 2 | 2010 | 45 | 0.100 |
Why?
|
| Pregnancy | 4 | 2023 | 3237 | 0.100 |
Why?
|
| Membrane Potentials | 3 | 2005 | 442 | 0.100 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2013 | 73 | 0.100 |
Why?
|
| Phrenic Nerve | 1 | 2013 | 49 | 0.100 |
Why?
|
| KATP Channels | 1 | 2013 | 20 | 0.100 |
Why?
|
| Calcium Channels, Q-Type | 1 | 2013 | 8 | 0.100 |
Why?
|
| Calcium Channels, P-Type | 1 | 2013 | 10 | 0.100 |
Why?
|
| Stress, Psychological | 1 | 2016 | 347 | 0.100 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2018 | 106 | 0.100 |
Why?
|
| Mice, 129 Strain | 1 | 2013 | 57 | 0.100 |
Why?
|
| Ketanserin | 2 | 2010 | 10 | 0.100 |
Why?
|
| Piperazines | 2 | 2011 | 296 | 0.090 |
Why?
|
| Microglia | 2 | 2015 | 124 | 0.090 |
Why?
|
| Mitochondria | 1 | 2016 | 621 | 0.090 |
Why?
|
| Integrases | 1 | 2012 | 67 | 0.090 |
Why?
|
| Gap Junctions | 2 | 2017 | 147 | 0.090 |
Why?
|
| Picrotoxin | 1 | 2011 | 6 | 0.090 |
Why?
|
| Deferoxamine | 1 | 2011 | 18 | 0.090 |
Why?
|
| T-Box Domain Proteins | 1 | 2013 | 129 | 0.090 |
Why?
|
| Ferrous Compounds | 1 | 2011 | 18 | 0.090 |
Why?
|
| Malondialdehyde | 1 | 2011 | 26 | 0.090 |
Why?
|
| Synaptic Potentials | 1 | 2011 | 17 | 0.090 |
Why?
|
| Siderophores | 1 | 2011 | 22 | 0.090 |
Why?
|
| Lipid Peroxidation | 1 | 2011 | 47 | 0.090 |
Why?
|
| Infant Mortality | 2 | 2023 | 67 | 0.090 |
Why?
|
| Piperidines | 2 | 2010 | 171 | 0.090 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2011 | 9 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1346 | 0.090 |
Why?
|
| Cardiovascular System | 1 | 2011 | 64 | 0.090 |
Why?
|
| Motor Activity | 2 | 2016 | 332 | 0.090 |
Why?
|
| Egtazic Acid | 1 | 2011 | 33 | 0.090 |
Why?
|
| TRPM Cation Channels | 1 | 2011 | 9 | 0.090 |
Why?
|
| Phenanthrenes | 1 | 2011 | 4 | 0.090 |
Why?
|
| Age Factors | 3 | 2019 | 1957 | 0.090 |
Why?
|
| Transient Receptor Potential Channels | 1 | 2011 | 5 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 848 | 0.080 |
Why?
|
| Light | 1 | 2012 | 297 | 0.080 |
Why?
|
| Chelating Agents | 1 | 2011 | 68 | 0.080 |
Why?
|
| Mice, Mutant Strains | 2 | 2019 | 232 | 0.080 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2010 | 7 | 0.080 |
Why?
|
| Calcium Channel Blockers | 2 | 2014 | 122 | 0.080 |
Why?
|
| Isoindoles | 1 | 2010 | 15 | 0.080 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 2010 | 15 | 0.080 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2010 | 8 | 0.080 |
Why?
|
| Receptors, Serotonin, 5-HT2 | 1 | 2010 | 15 | 0.080 |
Why?
|
| Locus Coeruleus | 1 | 2010 | 8 | 0.080 |
Why?
|
| Anesthetics, Local | 2 | 2010 | 84 | 0.080 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2013 | 677 | 0.080 |
Why?
|
| Microinjections | 1 | 2010 | 71 | 0.080 |
Why?
|
| Neurokinin-1 Receptor Antagonists | 1 | 2010 | 35 | 0.080 |
Why?
|
| Raphe Nuclei | 1 | 2010 | 38 | 0.080 |
Why?
|
| Electromyography | 1 | 2010 | 201 | 0.080 |
Why?
|
| Mutation, Missense | 2 | 2022 | 302 | 0.080 |
Why?
|
| Dopamine | 1 | 2011 | 283 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 2 | 2012 | 312 | 0.070 |
Why?
|
| Finches | 1 | 2009 | 59 | 0.070 |
Why?
|
| Biological Evolution | 1 | 2016 | 1030 | 0.070 |
Why?
|
| Genetic Vectors | 2 | 2025 | 446 | 0.070 |
Why?
|
| Regional Blood Flow | 1 | 2008 | 197 | 0.070 |
Why?
|
| Vocalization, Animal | 1 | 2009 | 104 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 358 | 0.070 |
Why?
|
| Presenilin-1 | 1 | 2008 | 97 | 0.070 |
Why?
|
| Aging | 1 | 2013 | 766 | 0.070 |
Why?
|
| Cell Survival | 2 | 2017 | 1029 | 0.060 |
Why?
|
| Hibernation | 1 | 2007 | 5 | 0.060 |
Why?
|
| Adult | 2 | 2024 | 28578 | 0.060 |
Why?
|
| Cerebrovascular Circulation | 1 | 2008 | 243 | 0.060 |
Why?
|
| Cell Membrane | 3 | 2004 | 687 | 0.060 |
Why?
|
| Species Specificity | 1 | 2008 | 707 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2014 | 2929 | 0.060 |
Why?
|
| Death, Sudden | 1 | 2006 | 42 | 0.060 |
Why?
|
| Respiratory System Abnormalities | 1 | 2005 | 5 | 0.060 |
Why?
|
| Stem Cells | 1 | 2008 | 394 | 0.060 |
Why?
|
| Visual Cortex | 1 | 2008 | 265 | 0.060 |
Why?
|
| Cadmium Chloride | 1 | 2005 | 12 | 0.060 |
Why?
|
| Nifedipine | 1 | 2005 | 26 | 0.060 |
Why?
|
| Tetraethylammonium | 1 | 2005 | 24 | 0.060 |
Why?
|
| Cations | 1 | 2025 | 32 | 0.060 |
Why?
|
| Environment | 1 | 2007 | 231 | 0.060 |
Why?
|
| Cell Proliferation | 3 | 2018 | 1753 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 2013 | 908 | 0.050 |
Why?
|
| Lipid Bilayers | 1 | 2025 | 147 | 0.050 |
Why?
|
| Cholinergic Agents | 1 | 2024 | 17 | 0.050 |
Why?
|
| Decerebrate State | 1 | 2003 | 4 | 0.050 |
Why?
|
| Animal Experimentation | 1 | 2003 | 9 | 0.050 |
Why?
|
| Nervous System Physiological Phenomena | 1 | 2003 | 18 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2006 | 522 | 0.050 |
Why?
|
| Hawaii | 1 | 2023 | 26 | 0.050 |
Why?
|
| Halothane | 1 | 2023 | 13 | 0.050 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2023 | 2 | 0.050 |
Why?
|
| Alzheimer Disease | 1 | 2008 | 606 | 0.050 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2002 | 15 | 0.050 |
Why?
|
| Consciousness | 1 | 2023 | 32 | 0.050 |
Why?
|
| Electric Conductivity | 1 | 2002 | 147 | 0.050 |
Why?
|
| Spinal Cord | 1 | 2024 | 252 | 0.050 |
Why?
|
| Ion Channel Gating | 1 | 2025 | 338 | 0.050 |
Why?
|
| KCNQ Potassium Channels | 1 | 2022 | 7 | 0.050 |
Why?
|
| Death | 1 | 2023 | 97 | 0.050 |
Why?
|
| Gestational Age | 1 | 2023 | 343 | 0.050 |
Why?
|
| Cricetulus | 1 | 2022 | 132 | 0.050 |
Why?
|
| HSC70 Heat-Shock Proteins | 1 | 2002 | 5 | 0.050 |
Why?
|
| HSP72 Heat-Shock Proteins | 1 | 2002 | 24 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2023 | 137 | 0.050 |
Why?
|
| Protein Kinase C | 1 | 2002 | 265 | 0.040 |
Why?
|
| Potassium Channels | 1 | 2024 | 359 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2023 | 259 | 0.040 |
Why?
|
| Models, Biological | 1 | 2008 | 1809 | 0.040 |
Why?
|
| Cricetinae | 1 | 2022 | 542 | 0.040 |
Why?
|
| Temperature | 1 | 2003 | 426 | 0.040 |
Why?
|
| Endocytosis | 1 | 2022 | 186 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2022 | 329 | 0.040 |
Why?
|
| Reference Values | 1 | 2002 | 674 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2002 | 118 | 0.040 |
Why?
|
| Infant Care | 1 | 2020 | 7 | 0.040 |
Why?
|
| Supine Position | 1 | 2020 | 34 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2003 | 423 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2023 | 3106 | 0.040 |
Why?
|
| Prone Position | 1 | 2020 | 62 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2002 | 348 | 0.040 |
Why?
|
| Geography, Medical | 1 | 2020 | 2 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2021 | 358 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2023 | 483 | 0.040 |
Why?
|
| Kinetics | 1 | 2002 | 1561 | 0.040 |
Why?
|
| Beds | 1 | 2019 | 7 | 0.040 |
Why?
|
| Monitoring, Ambulatory | 2 | 2011 | 33 | 0.040 |
Why?
|
| Asphyxia | 1 | 2019 | 12 | 0.040 |
Why?
|
| Genes, X-Linked | 1 | 2020 | 39 | 0.040 |
Why?
|
| Exons | 1 | 2021 | 454 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 1006 | 0.040 |
Why?
|
| Choline O-Acetyltransferase | 1 | 2019 | 25 | 0.040 |
Why?
|
| Bicuculline | 2 | 2010 | 19 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2002 | 252 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2020 | 82 | 0.040 |
Why?
|
| Recombinases | 1 | 2019 | 22 | 0.040 |
Why?
|
| Reactive Nitrogen Species | 1 | 2018 | 9 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 701 | 0.040 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2018 | 23 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2019 | 220 | 0.040 |
Why?
|
| Free Radical Scavengers | 1 | 2018 | 60 | 0.040 |
Why?
|
| Maternal Behavior | 1 | 2019 | 56 | 0.040 |
Why?
|
| Cause of Death | 1 | 2019 | 278 | 0.040 |
Why?
|
| Neuropeptides | 1 | 2018 | 116 | 0.040 |
Why?
|
| Phenotype | 1 | 2025 | 2575 | 0.030 |
Why?
|
| GABA-A Receptor Antagonists | 2 | 2010 | 15 | 0.030 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2019 | 176 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2018 | 187 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2019 | 171 | 0.030 |
Why?
|
| Adolescent | 4 | 2011 | 9873 | 0.030 |
Why?
|
| Self Report | 1 | 2019 | 328 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2018 | 324 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2019 | 713 | 0.030 |
Why?
|
| Miniature Postsynaptic Potentials | 1 | 2016 | 6 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 880 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2021 | 825 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2020 | 594 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2017 | 256 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2016 | 81 | 0.030 |
Why?
|
| Glycine Agents | 2 | 2008 | 5 | 0.030 |
Why?
|
| Acoustic Stimulation | 1 | 2016 | 131 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1267 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 1010 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1714 | 0.030 |
Why?
|
| Bradykinin | 1 | 2014 | 46 | 0.030 |
Why?
|
| Receptors, Glutamate | 1 | 2014 | 24 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2015 | 305 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2013 | 1662 | 0.030 |
Why?
|
| Ganglia, Spinal | 1 | 2014 | 76 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 1878 | 0.030 |
Why?
|
| Receptors, Cholinergic | 1 | 2014 | 77 | 0.030 |
Why?
|
| Photic Stimulation | 1 | 2016 | 514 | 0.030 |
Why?
|
| Histamine | 1 | 2014 | 124 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1540 | 0.020 |
Why?
|
| Nestin | 1 | 2013 | 18 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2013 | 58 | 0.020 |
Why?
|
| Intermediate Filament Proteins | 1 | 2013 | 35 | 0.020 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2013 | 68 | 0.020 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2013 | 34 | 0.020 |
Why?
|
| Stem Cell Niche | 1 | 2013 | 24 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 2061 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2013 | 49 | 0.020 |
Why?
|
| Plethysmography, Whole Body | 1 | 2012 | 9 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2013 | 224 | 0.020 |
Why?
|
| Microscopy, Video | 1 | 2012 | 36 | 0.020 |
Why?
|
| Gliosis | 1 | 2012 | 32 | 0.020 |
Why?
|
| Vestibular Nuclei | 1 | 2012 | 28 | 0.020 |
Why?
|
| Halorhodopsins | 1 | 2012 | 6 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2012 | 77 | 0.020 |
Why?
|
| Channelrhodopsins | 1 | 2012 | 9 | 0.020 |
Why?
|
| Optics and Photonics | 1 | 2012 | 26 | 0.020 |
Why?
|
| Apnea | 1 | 2012 | 31 | 0.020 |
Why?
|
| GATA3 Transcription Factor | 1 | 2012 | 52 | 0.020 |
Why?
|
| Electrophysiological Phenomena | 1 | 2012 | 52 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2013 | 314 | 0.020 |
Why?
|
| Tamoxifen | 1 | 2013 | 171 | 0.020 |
Why?
|
| Electroporation | 1 | 2012 | 57 | 0.020 |
Why?
|
| Rhombencephalon | 1 | 2012 | 49 | 0.020 |
Why?
|
| Archaeal Proteins | 1 | 2012 | 26 | 0.020 |
Why?
|
| Cell Count | 1 | 2012 | 202 | 0.020 |
Why?
|
| Vagus Nerve | 1 | 2011 | 50 | 0.020 |
Why?
|
| Magnesium | 1 | 2012 | 178 | 0.020 |
Why?
|
| RNA, Untranslated | 1 | 2012 | 69 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2012 | 312 | 0.020 |
Why?
|
| Luminescent Proteins | 1 | 2012 | 145 | 0.020 |
Why?
|
| Adrenergic alpha-2 Receptor Antagonists | 1 | 2011 | 4 | 0.020 |
Why?
|
| Serotonin 5-HT2 Receptor Agonists | 1 | 2011 | 4 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2012 | 286 | 0.020 |
Why?
|
| Animals, Outbred Strains | 1 | 2011 | 17 | 0.020 |
Why?
|
| Sympathetic Nervous System | 1 | 2011 | 99 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2019 | 2480 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 417 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1535 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2010 | 43 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 301 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 2777 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 515 | 0.020 |
Why?
|
| Cholinergic Fibers | 1 | 2009 | 24 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 630 | 0.020 |
Why?
|
| Neurochemistry | 1 | 2009 | 2 | 0.020 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2009 | 31 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 3990 | 0.020 |
Why?
|
| Oxotremorine | 1 | 2008 | 4 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2008 | 99 | 0.020 |
Why?
|
| Muscarinic Agonists | 1 | 2008 | 23 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2008 | 372 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2008 | 296 | 0.020 |
Why?
|
| Social Environment | 1 | 2008 | 195 | 0.020 |
Why?
|
| Proteins | 1 | 2012 | 816 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 2385 | 0.010 |
Why?
|
| Heart | 1 | 2008 | 590 | 0.010 |
Why?
|
| Disease Progression | 1 | 2009 | 1559 | 0.010 |
Why?
|
| Lanthanum | 1 | 2004 | 16 | 0.010 |
Why?
|
| Receptors, GABA-A | 1 | 2004 | 35 | 0.010 |
Why?
|
| Receptors, Glycine | 1 | 2004 | 11 | 0.010 |
Why?
|
| Cytokines | 1 | 2008 | 871 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2017 | 9167 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2002 | 278 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 3639 | 0.010 |
Why?
|